Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors

Inclusion Criteria: * Pregnant woman, under 15 weeks gestational age at screening * Documented Human Immunodeficiency Virus (HIV) HIV-1 infection (serology and/or plasma HIV RNA viral load) * Current treatment with at least two ARVs * Virological suppression for at least 12 months, defined by a PVL \< 50 copies / mL. A blip (transiently ≥ 50 but \< 400 copies/mL) will not be considered as an exclusion criterion, if it is followed by 2 successive controls with CV \< 50 at least one month before enrollment * Plasma viral load \< 50 copies/mL at pre-inclusion * CD4 ≥ 250 cells/mm3 at pre-inclusion * Informed written consent * Health care coverage Inclusion criteria for the child : * Mother enrolled in the trial * Informed written consent by parents or legal guardians Exclusion Criteria: * Infection by HIV-2 * History of treatment failure and/or resistance with any Protease Inhibitor (PI). Treatment failure is defined by a viral replication (≥ 50 copies/mL) during antiretroviral treatment. An increasing CV due to treatment interruption will not be considered as a failure, providing that the absence of resistance mutations to at least one PI can be confirmed by genotyping. * Documented CD4 lymphocyte less than 200/mm3 * Known intolerance to darunavir or ritonavir * Hepatitis B Virus (HBV) co-infection (HBs Ag-positive and/or detectable HBV DNA) on therapy with analogs (tenofovir, emtricitabine, lamivudine) * Known resistance of maternal viral strain to darunavir or nevirapine…